[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"intraoperative-bleeding\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:intraoperative-bleeding":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,52,75,103],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":30,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100639010","reducing-red-blood-cell-transfusion-requirements-for-adults-undergoing-surgical-resection-of-the-liver---a-quality-improvement-project-100639010",false,"NCT07629648","Reducing Red Blood Cell Transfusion Requirements for Adults Undergoing Surgical Resection of the Liver - A Quality Improvement Project","Reducing Red Blood Cell Transfusion Requirements for Hepatectomy - A Quality Improvement Project","Inclusion Criteria:\n\n* Liver resection in this study is defined according to the PRICE-2 trial, involving 3 or more liver segments, such as right posterior sectionectomy (of segments VI and VII) as well as central resections involving segments IVb and V, along with expected blood loss of \\>250 mL\n* in patients with known liver cirrhosis, resection of a full segment was included.\n\nExclusion Criteria (defined according to the PRICE-2 trial):\n\n* current cardiac condition (e.g., MI within the last 6 months, hypertrophic cardiomyopathy, severe valvular disease, or other unstable coronary syndromes)\n* history of cerebrovascular disease (CVA within the past 6 months or severe carotid stenosis with more than 70% occlusion)\n* history of significant peripheral vascular disease (not yet revascularized with regular\u002Fongoing claudication)\n* A current pregnancy\n* A documented, patient-declared refusal to undergo phlebotomy and transfusion\n* preoperative autologous blood donation\n* presence of active infection\n* preoperative hemoglobin \\\u003C100 g\u002FL\n* GFR \\\u003C60 mL\u002Fmin\n* platelets count \\\u003C100 × 109\u002FL\n* Uncorrectable coagulopathies or other decompensated cardiac or respiratory conditions that would contraindicate acute volume depletion\n* undergoing emergency surgery\n* planned intraoperative use of cell salvage\n* inability to participate in follow up\n* in the case of repeat liver resections, previous participation in the trial","ALL","18 Years",{"count":19,"type":20},60,"ESTIMATED","OBSERVATIONAL","The goal of this clinical trial is to determine if implementing a controlled blood removal protocol (i.e. hypovolemic phlebotomy \\[HP\\] where approximately 10% of the patient's blood is removed and reinfused following hepatic resection as described in the PRICE-2 clinical trial) will reduce the rate of blood transfusions in liver resection surgery at Kingston Health Sciences Centre. Our goals (not included in the PRICE-2 trial) are as follows:\n\n* Improved monitoring of how the body responds during surgery following controlled blood removal. We will conduct blood tests to look at oxygen, carbon dioxide, lactate, and acid (pH) levels in the blood as well as urine output.\n* Standardized guidelines for how fluids and blood pressure medications are used during surgery to reduce blood loss and keep hemodynamics stable.\n* Monitor patients' recovery following surgery to track complications, injury to the heart, length of hospital stay, and outcomes for up to 90 days. We will also compare long-term recurrence rate of liver cancer compared to patients in the past at our site who did not receive the controlled blood removal (i.e., HP) prior to surgery.",[24,25,26,27,28,29],"Hepatectomy","Transfusion Requirements","Intraoperative Bleeding","Intraoperative Monitoring","Blood Cells Transfusion","Phlebotomy",[31,32,33,34,35,36,37,38],"hypovolemic phlebotomy","hepatectomy","Perioperative Care","erythrocyte transfusion","liver resection","transfusion requirements","therapeutic phlebotomy","intraoperative bleeding","NOT_YET_RECRUITING","2026-06-01",{"date":42,"type":43},"2026-06-05","ACTUAL",{"date":45,"type":20},"2026-06",{"date":47,"type":20},"2031-06",{"name":49,"class":50},"Dr. Glenio Mizubuti (MD, PhD, FRCPC)","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":61,"conditions":62,"keywords":63,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":4},"100606779","ddavp-effect-by-teg6-in-cardiac-surgery-100606779","NCT07179991","DDAVP Effect by TEG6 in Cardiac Surgery","Desmopressin Effect on Platelet Function Assessment by Thromboelastography (TEG 6) in Cardiac Surgery","Inclusion Criteria:\n\n1. Age 18 years and above\n2. Undergoing elective cardiac surgery with cardiopulmonary bypass\n3. Able to provide informed consent\n\nExclusion Criteria:\n\n1. Hyponatremia\n2. Allergy to desmopressin or its components\n3. History of coronary artery disease with thrombosis\n4. Recent history of thromboembolic events (Stroke\u002FTIA\u002FDVTs)\n5. Severe Renal Impairment Creatinine Clearance\\\u003C30 ml\u002Fmin\n6. Inability to communicate in the English language",{"count":60,"type":20},100,"Cardiopulmonary bypass (CPB) is a process that uses a pump that temporarily takes over the function of the heart and lungs during cardiac surgery to maintain blood circulation and oxygenation. Using CPB during cardiac surgery can result in complications with blood clotting. Blood clotting is achieved when molecules in the blood, called platelets, are able to form together with the help of other clotting factors to form a clot. A drug called desmopressin (DDAVP) is used to help blood clot properly by increasing the amount of clotting factors in the blood. Several studies have shown that desmopressin has the ability to reduce the amount of blood transfusions needed for cardiac surgery patients in the postoperative period. At LHSC desmopressin is frequently requested by Cardiac Surgeons and Anesthesiologists to stop bleeding and promote blood clotting where required. A test called TEG6s platelet mapping is a blood test used to help manage the use of blood products by being able to provide information on platelet function and blood clotting activity. At the moment, there is a lack of information regarding the use of TEG6s platelet mapping to analyze the effect of desmopressin on blood clotting in cardiac surgery patients after CPB. The purpose of this study is to investigate the dose-related effects of desmopressin on platelet function in patients undergoing cardiac surgery with CPB. By using TEG6s platelet mapping, this study aims to observe dynamic changes in platelet function following desmopressin administration at various time points in the perioperative and postoperative periods.",[26],[64,65],"Desmopressin","Cardiopulmonary bypass","2025-09-11",{"date":68,"type":43},"2025-09-18",{"date":70,"type":20},"2025-10-01",{"date":72,"type":20},"2027-12-31",{"name":74,"class":50},"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":85,"phases":86,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":99,"leadSponsor":101,"locationsCount":51},"100581319","lidocaine-and-dexmedetomidine-infusions-for-intraoperative-bleeding-in-functional-endoscopic-sinus-surgery-100581319","NCT06848764","Lidocaine and Dexmedetomidine Infusions for Intraoperative Bleeding in Functional Endoscopic Sinus Surgery","A Randomized Double-Blind Trial Comparing Lidocaine and Dexmedetomidine Infusions for Intraoperative Bleeding in Patients Undergoing Functional Endoscopic Sinus Surgery","Inclusion Criteria:\n\n* Age from 18 to 65 years old.\n* American Society of Anesthesiologists (ASA) physical status I - II.\n* Scheduled for elective functional endoscopic sinus surgery.\n\nExclusion Criteria:\n\n* Diabetes mellitus.\n* Coagulation disorders.\n* Kidney and liver dysfunction.\n* Cerebrovascular disease.\n* Cardiovascular problems.\n* High blood pressure.\n* Asthma.\n* Chronic obstructive pulmonary disease (COPD).\n* End organ damage.\n* Psychosis.\n* Taking antipsychotic drugs.\n* Allergy to study drugs.\n* Substance abuse.\n* Taking beta blockers.\n* Heart rate of \\\u003C 55 beat\u002Fminute.","65 Years",{"count":84,"type":20},40,"INTERVENTIONAL",[87],"NA","This work aims to compare lidocaine and dexmedetomidine infusions for intraoperative bleeding in patients undergoing functional endoscopic sinus surgery.",[90,91,92,26,93],"Lidocaine","Dexmedetomidine","Infusion","Functional Endoscopic Sinus Surgery","RECRUITING","2025-03-01",{"date":97,"type":43},"2025-03-05",{"date":95,"type":43},{"date":100,"type":20},"2025-09-01",{"name":102,"class":50},"Ain Shams University",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":110,"enrollmentInfo":111,"targetDuration":4,"studyType":85,"phases":113,"briefSummary":116,"conditions":117,"keywords":4,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":51},"100548954","phase-2-the-effect-of-adding-either-propofol-or-ketamine-to-magnesium-and-lidocaine-infusions-in-nasal-surgeries-100548954","NCT06427707","The Effect of Adding Either Propofol or Ketamine to Magnesium and Lidocaine Infusions in Nasal Surgeries.","The Effect of Adding Either Propofol or Ketamine to Magnesium and Lidocaine Infusions As an Opioid Free Anaesthesia on Surgical Field in Patients Undergoing Nasal Surgeries. a Randomized Controlled Trial","Inclusion Criteria:\n\n* ASA I-II,\n* scheduled for elective nasal surgery\n\nExclusion Criteria:\n\n* Patients with uncontrolled hypertension.\n* Patients with cardiac disease.\n* Patients with renal, hepatic or cerebral insufficiency.\n* Patients with coagulopathy or receiving drugs influencing blood coagulation.\n* Anaemia, haemoglobinopathies or polycythemia.\n* Pregnancy.\n* Patients with known sensitivity to any of the study drug.","60 Years",{"count":112,"type":20},90,[114,115],"PHASE2","PHASE3","Nasal surgeries are common day case procedures. Although surgical complications are rare, bleeding decreases surgical field visibility and may cause vascular, orbital or intracranial complications in addition to failure of procedure. So, it is crucial to maintain hypotensive anaesthesia to optimize the surgical field.",[26],"2024-10-05",{"date":120,"type":43},"2024-10-09",{"date":122,"type":43},"2024-06-15",{"date":124,"type":20},"2024-10-31",{"name":102,"class":50}]